Current Headlines

1. Company Licenses Drug Development Compounds From UWM Research Foundation 8/13/2020

   New Jersey-based RespireRx Pharmaceuticals Inc. has licensed a group of patented drug development compounds from the University of Wisconsin-Milwaukee Research Foundation

2. BioSymetrics Joins Accenture's INTIENT Network 8/13/2020

   BioSymetrics, a biomedical artificial intelligence company that helps researchers develop drugs with greater speed and precision, announced it has joined Accenture's partner ecosystem, designed to help independent software vendors (ISVs) and life science companies integrate more effectively to accelerate drug discovery efforts and improve patient outcomes

3. ChemDiv Created Unique KATO TM Platform For Development Of Innovative Drugs Against Coronavirus Infection 8/13/2020

   ChemDiv Inc., a fully integrated California-based CRO, announced today the creation of a unique platform for development of drugs against coronavirus infection that would simplify and accelerate antiviral candidate selection

4. Scipher Medicine And Galapagos Sign Collaboration In inflammatory Bowel Disease 8/12/2020

   Mechelen, Belgium and Boston, USA; 12 August 2020 - Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD)

5. Innovent And Eli Lilly Announce Acceptance Of A Supplemental New Drug Application Of TYVYT® (Sintilimab Injection) In Combination With Gemcitabine And Platinum As First-Line Therapy In Squamous Non-Small Cell Lung Cancer In China 8/12/2020

   Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today jointly announced with Eli Lilly and Company ("Lilly",NYSE: LLY) that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with Gemzar® (gemcitabine) and platinum as first-line therapy in squamous non-small cell lung cancer (squamous NSCLC). Recently, the NMPA accepted sNDA for TYVYT® (sintilimab injection) as first-line therapy in non-squamous NSCLC on Apr 23, 2020

6. Scientists Identify Hundreds Of Drug Candidates To Treat COVID-19 8/11/2020

   Scientists at the University of California, Riverside, have used machine learning to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2

7. Modelling Parasitic Worm Metabolism Suggests Strategy For Developing New Drugs Against Infection 8/11/2020

   Scientists have revealed a way to eradicate parasitic worms by stopping them from using alternative metabolism pathways provided by bacteria that live within them, according to new findings published today in eLife

8. Gilead Submits New Drug Application To U.S. Food And Drug Administration For Veklury (Remdesivir) For The Treatment Of COVID-19 8/10/2020

   Gilead Sciences, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Veklury (remdesivir), an investigational antiviral for the treatment of patients with COVID-19

9. Clearside Biomedical Announces U.S. FDA Acceptance Of Investigational New Drug Application For CLS-AX (Axitinib Injectable Suspension) Administered In Suprachoroidal Space 8/10/2020

   Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for CLS-AX (axitinib injectable suspension), enabling initiation of a Phase 1/2a clinical trial of CLS-AX in neovascular age-related macular degeneration (wet AMD) patients by the end of 2020

10. SFU Chemist’s New Process Fast-Tracks Drug Treatments For Viral Infections And Cancer 8/7/2020

    Discovering antiviral and anticancer drugs will soon be faster and cheaper thanks to new research from SFU chemist Robert Britton and his international team